|
publisher: Wiley, published: 2009-10-12
ASIN: 0470117915
EAN: 9780470117910
sales rank: 348160
70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories
|
|
publisher: Wiley, published: 2010-08-09
ASIN: 0470243724
EAN: 9780470243725
sales rank: 462537
Oncology Book of 2011, British Medical Association's Medical Book AwardsAwarded first prize in the Oncology category at the 2011 BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments. Expert discussion covers a range of diverse topics associated with this field, including the optimization of design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from key clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. With chapters authored by internationally renowned experts, this book delivers a wealth of information to push future discovery.
|
|
by: Robert K. Scopes
publisher: Springer, published: 1993-11-19
ASIN: 0387940723
EAN: 9780387940724
sales rank: 419279
The third edition of this classic guide to protein purification updates methods, principles and references. As in the widely-acclaimed earlier editions, Scopes guides both the novice and the experienced researcher from theory to application. Using the book, the reader is able to integrate methods effectively into optimum protocols for the task at hand. Reviews of earlier editions: "good practical advice that is presented in a pleasantly readable form" --Analytical Biochemistry "well organized and written clearly" --American Scientist "should be on every laboratory shelf where protein are being handled or purified...a feast and a genuine pleasure to read" --Nature
|
|
publisher: Wiley-Interscience, published: 2009-02-09
ASIN: 0470209623
EAN: 9780470209622
sales rank: 576758
Traditional column chromatography dominates current purification technology, and many of the productivity gains that have been achieved have relied on upscaling such devices. However, this comes with a cost penalty and the pharmaceutical industry has reached the point at which further upscaling becomes economically unsupportable. This book offers a broad-based reassessment of old and new purification methods, incorporating an analysis of innovative new trends in purification. The book has wide coverage of different antibody purification strategies and brings together top-tier experts to address problems in process-scale antibody purification.
|
|
by: David J. King
publisher: CRC Press, published: 1998-12
ASIN: 0748404236
EAN: 9780748404230
sales rank: 4844509
A valuable resource for researchers and workers in the fields of both pharmaceuticals and biotechnology as well as undergraduates in biochemistry, applied biology, biomedical sciences and pharmacy, this book compares established techniques of antibody production with the new. Antibody structure and the implications of antibody engineering are fully discussed, and a case study approach illustrates how antibodies are finding increasing use in the diagnosis and treatment of disease. The volume ends with commercial expression, purification and large-scale manufacture of antibodies and their future potential, particularly as therapeutic agents.
|
|
publisher: Humana Press, published: 1987-08-03
ASIN: 0896031004
EAN: 9780896031005
sales rank: 592238
|
|
publisher: Springer, published: 2009-11-12
ASIN: 0387766421
EAN: 9780387766423
sales rank: 1125065
Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade. Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.
|
|
by: James W. Goding
publisher: Academic Press, published: 1996-03-19
ASIN: 0122870239
EAN: 9780122870231
sales rank: 1608790
Monoclonal Antibodies now have applications in virtually all areas of biology and medicine, and much of the world's biotechnology industry has its foundations in the exploitation of this technology. The Third Edition of this well established book meets the needs of both newcomers to the area and experienced researchers, by providing an integrated treatment of both the production and application of monoclonal antibodies. As in previous editions, detailed and critical accounts of the theory, production, purification, fragmentation, storage and radiolabelling of monoclonal antibodies are given, along with descriptions of their use in antigen characterization, affinity chromatography and immunofluorescence. The present volume has been comprehensively updated to cover recent rapid advances, particularly with respect to the applications of molecular biology, the use of antibodies in closing and heterologous expression of genes, immunohistology and phage display libraries. Since the previous edition, there has been a growing trend towards the replacement of procedures using radioactive isotopes, and the current edition incorporates these newer technologies. The text is oriented towards problems solving, and makes it easy to adapt each procedure to individual needs. Extensive cross-referencing, a glossary and a comprehensive index make this book an essential reference. This book will be vital both for laboratories already producing or using monoclonal antibodies, and for workers in many disciplines who are contemplating their use.
* * Provides an integrated treatment of both the production and application of monoclonals in cell biology, biochemistry, and immunology. * Gives detailed and critical accounts of the theory, production, purification, storage, and relabelling of monoclonals, and their use in antigen characterization, affinity chromorography, and immunofluroscence. * Comprehensively updated to cover the rapid advances that have occurred since the publication of the Second Edition.
|
|
publisher: Springer, published: 2010-11-29
ASIN: 9048179564
EAN: 9789048179565
sales rank: 4063465
The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future. The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology. It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.
|
|
|
by: Pete Gagnon
publisher: Validated Biosystems Inc, published: 1996-01-31
ASIN: 0965351599
EAN: 9780965351591
sales rank: 2466584
|